HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Galderma Differin -vs- J&J Retin-A

This article was originally published in The Rose Sheet

Executive Summary

Galderma Differin -vs- J&J Retin-A: Results from three Galderma studies comparing the irritation potential of Differen (adapalene .1%) in different gel vehicles with Retin-A (tretinoin gel .025%) found that adapalene gel "was very well tolerated when applied topically in standard cumulative irritation tests" and was relatively non-irritating when used on facial skin. Tretinoin under similar testing conditions "produced severe irritation reactions resulting in treatment discontinuation in many cases," according to the Galderma researchers. Galderma's analysis of two large multi-centered Phase I trials on the safety and efficacy of the two ingredients concluded that the 295 tretinoin users in both studies combined reported higher numbers of cutaneous events that the 296 adapalene users. Galderma has an NDA pending for adapalene 1%, a naphtholic acid derivative...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel